Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer

被引：18
|
作者：
Sharp, Adam [1 ,2 ]
Welti, Jonathan [1 ,2 ]
Blagg, Julian [3 ]
de Bono, Johann S. [1 ,2 ]
机构：
[1] Inst Canc Res, Prostate Canc Targeted Therapy Grp, Sutton, Surrey, England
[2] Royal Marsden NHS Fdn Trust, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England
[3] Inst Canc Res, Canc Res UK Canc Therapeut Unit, London, England
来源：
CLINICAL CANCER RESEARCH | 2016年 / 22卷 / 17期
基金：
英国医学研究理事会;
关键词：
DOMAIN;
D O I：
10.1158/1078-0432.CCR-16-1137
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. (C) 2016 AACR.
引用
收藏
页码：4280 / 4282
页数：3
相关论文
共 50 条
  • [31] Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
    X Yuan
    C Cai
    S Chen
    S Chen
    Z Yu
    S P Balk
    [J]. Oncogene, 2014, 33 : 2815 - 2825
  • [32] Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
    Yuan, X.
    Cai, C.
    Chen, S.
    Chen, S.
    Yu, Z.
    Balk, S. P. p
    [J]. ONCOGENE, 2014, 33 (22) : 2815 - 2825
  • [33] Androgen biosynthesis in castration-resistant prostate cancer
    Penning, Trevor M.
    [J]. ENDOCRINE-RELATED CANCER, 2014, 21 (04) : T67 - T78
  • [34] Alternative polyadenylation of androgen receptor variants in castration-resistant prostate cancer
    Van Etten, Jamie L.
    Nyquist, Michael
    Li, Yingming
    LaRue, Rebecca
    Ho, Yeung
    Yang, Rendong
    Voytas, Daniel F.
    Henzler, Christine
    Dehm, Scott M.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [35] Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer
    Won Kim
    Charles J Ryan
    [J]. Current Treatment Options in Oncology, 2012, 13 : 189 - 200
  • [36] Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
    Perner, Sven
    Cronauer, Marcus V.
    Schrader, Andres Jan
    Klocker, Helmut
    Culig, Zoran
    Baniahmad, Aria
    [J]. ONCOTARGET, 2015, 6 (34) : 35542 - 35555
  • [37] Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
    Conteduca, Vincenza
    Jayaram, Anuradha
    Romero-Laorden, Nuria
    Wetterskog, Daniel
    Salvi, Samanta
    Gurioli, Giorgia
    Scarpi, Emanuela
    Castro, Elena
    Marin-Aguilera, Mercedes
    Lolli, Cristian
    Schepisi, Giuseppe
    Maugeri, Antonio
    Wingate, Anna
    Farolfi, Alberto
    Casadio, Valentina
    Medina, Ana
    Puente, Javier
    Mendez Vidal, Ma Jose
    Morales-Barrera, Rafael
    Villa-Guzman, Jose C.
    Hernando, Susana
    Rodriguez-Vida, Alejo
    Gonzalez-del-Alba, Aranzazu
    Mellado, Begona
    Gonzalez-Billalabeitia, Enrique
    Olmos, David
    Attard, Gerhardt
    De Giorgi, Ugo
    [J]. EUROPEAN UROLOGY, 2019, 75 (03) : 368 - 373
  • [38] Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
    George, Daniel J.
    Morgans, Alicia K.
    Constantinovici, Niculae
    Khan, Nasreen
    Khan, Javeed
    Chen, Guifang
    Hlebec, Vlasta
    Shore, Neal D.
    [J]. JAMA NETWORK OPEN, 2024, 7 (08)
  • [39] Spironolactone: A selective androgen receptor modulator in castration-resistant prostate cancer
    Barthelemy, Philippe
    Erdmann, Eva
    Duclos, Brigitte
    Bergerat, Jean Pierre
    Kurtz, Jean-Emmanuel
    Ceraline, Jocelyn
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [40] Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
    Obinata, Daisuke
    Lawrence, Mitchell G.
    Takayama, Kenichi
    Choo, Nicholas
    Risbridger, Gail P.
    Takahashi, Satoru
    Inoue, Satoshi
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
12345